I do think one side is heavier than the other (that the trial has better than 50% to be successful), but not so much because of the 'depleting the stroma' theory. Btw, are they looking at SPARC expression level in tumors of patients in the ongoing phase III trial?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.